Detection and clinical significance of circulating tumor cells in colorectal cancer—20 years of progress

Molecular Medicine

Volumn 21, Issue , 2015, Pages S25-S31

  Hardingham, Jennifer E ^a,b   Grover, Phulwinder ^a   Winter, Marnie ^c   Hewett, Peter J ^a   Price, Timothy J ^a,b   Thierry, Benjamin ^c  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACHAETESCUTE COMPLEX HOMOLOG 2; BMI1 PROTEIN; CELL MARKER; EPITHELIAL CELL ADHESION MOLECULE; OLFACTOMEDIN 4; PROTEIN LGR5; UNCLASSIFIED DRUG; ASCL2 PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BIOLOGICAL MARKER; G PROTEIN COUPLED RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; LGR5 PROTEIN, HUMAN; OLFM4 PROTEIN, HUMAN;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER STEM CELL; CELL ISOLATION; CELL PROLIFERATION; CIRCULATING TUMOR CELL; COLORECTAL CANCER; COLORECTAL SURGERY; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GOLD STANDARD; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MICROFLUIDICS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; CELL SEPARATION; COLORECTAL NEOPLASMS; DEVICES; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; HISTORY; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; TUMOR EMBOLISM;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOMARKERS; CELL SEPARATION; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MICROFLUIDICS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; RECURRENCE;

EID: 84945948733     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00149     Document Type: Article

References (67)

1. Australian Institute of Health and Welfare (AIHW). (2014) Cancer in Australia: an overview 2014. Canberra: AIHW. Cancer series No. 90.
2. Siegel R, DeSantis C, Jemal A. (2014) Colorectal cancer statistics, 2014. CA Cancer J. Clin. 64:104-117.
3. Klein C. (2009) Parallel progression of primary tumours and metastases. Nat. Rev. Cancer. 9:302-312.
4. Hardingham JE, et al. (1995) Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol. Med. 1:789-794.
5. Tsavellas G, Patel H, Allen-Mersh TG. (2001) Detection and clinical significance of occult tumour cells in colorectal cancer. Br. J. Surg. 88:1307-1320.
6. Hardingham JE, et al. (2000) Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int. J. Cancer 89:8-13.
7. Sergeant G, Penninckx F, Topal B. (2008) Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood-a systematic review. J. Surg. Res. 150:144-152.
8. Torino F, et al. (2013) Circulating tumor cells in colorectal cancer patients. Cancer Treat. Rev. 39:759-772.
9. Alix-Panabieres C, Pantel K. (2014) Technologies for detection of circulating tumor cells: facts and vision. Lab Chip. 14:57-62.
10. Cole SR, et al. (2013) Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med. J. Aust. 198:327-330.
11. Roder D, et al. (2015) Colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pac. J. Cancer Prev. 16:2431-2440.
12. Bagshaw PF, et al. (2012) Long-term outcomes of the australasian randomized clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer: the Australasian Laparoscopic Colon Cancer Study trial. Ann. Surg. 256:915-919.
13. Lloyd JM, et al. (2006) Identification of early-stage colorectal cancer patients at risk of relapse postresection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin. Cancer Res. 12:417-423.
14. Gray R, et al. (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 370:2020-2029.
15. Pantel K, Brakenhoff RH, Brandt B. (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer. 8:329-340.
16. Hardingham JE, et al. (1993) Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 53:3455-3458.
17. Cristofanilli M, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl. J. Med. 351:781-791.
18. Riethdorf S, et al. (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13:920-928.
19. Cohen SJ, et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:3213-3221.
20. de Bono JS, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14:6302-6309.
21. Rahbari NN, et al. (2010) Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 138:1714-1726.e1713.
22. Groot Koerkamp B, Rahbari N, Büchler M, Koch M, Weitz J. (2013) Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann. Surg. Oncol. 20:2156-2165.
23. Pantel K, et al. (2012) Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 58:936-940.
24. Beije N, Jager A, Sleijfer S. (2015) Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer Treat. Rev. 41:144-150.
25. Lu CY, et al. (2013) Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br. J. Cancer. 108:791-797.
26. Krebs MG, et al. (2015) Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer. Clin. Colorectal Cancer. 14:115-122.
27. Bork U, et al. (2015) Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br. J. Cancer. 112:1306-1313.
28. Paterlini-Brechot P, Benali NL. (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 253:180-204.
29. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther. Adv. Med. Oncol. 2:351-365.
30. Tol J, et al. (2010) Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol. 21:1006-1012.
31. Rao CG, et al. (2005) Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int. J. Oncol. 27:49-57.
32. Gervasoni A, et al. (2011) Comparison of three distinct methods for the detection of circulating tumor cells in colorectal cancer patients. Oncol. Rep. 25:1669-1703.
33. Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. (2014) Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann. Oncol. 25:1506-1516.
34. Thurm H, et al. (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin. Cancer Res. 9:2598-2604.
35. Gorges T, et al. (2012) Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 12:178.
36. Labelle M, Begum S, Hynes RO. (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 20:576-590.
37. Polyak K, Weinberg RA. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer. 9:265-273.
38. Bednarz-Knoll N, Alix-Panabières C, Pantel K. (2012) Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 31:673-687.
39. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704-715.
40. Mitra A, Mishra L, Li S. (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 6:10697-10711.
41. Wicha MS, Hayes DF. (2011) Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 29:1508-1511.
42. van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW, den Toonder JMJ. (2011) Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res. 71:5955-5960.
43. Paterlini-Bréchot P. (2014) Circulating tumor cells: who is the killer? Cancer Microenviron. 7:161-176.
44. Pang R, et al. (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 6:603-615.
45. Iinuma H, et al. (2011) Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol. 29:1547-1555.
46. Valladares-Ayerbes M, et al. (2012) Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int. J. Mol. Sci. 13:4367-4387.
47. Han Y, et al. (2015) LGR5, a relevant marker of cancer stem cells, indicates a poor prognosis in colorectal cancer patients: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 39:267-273.
48. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. (2002) VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood. 101:168-172.
49. Koo B-K, Clevers H. (2014) Stem cells marked by the R-spondin receptor LGR5. Gastroenterology. 147:289-302.
50. Grover PK, Hardingham JE, Cummins AG. (2010) Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev. 29:761-775.
51. van der Flier LG, Haegebarth A, Stange DE, van de Wetering M, Clevers H. (2009) OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology. 137:15-17.
52. Barker N, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 449:1003-1007.
53. Sato T, et al. (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 141:1762-1772.
54. Yokobori T, et al. (2013) Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73:2059-2069.
55. Sanders MA, Majumdar APN. (2011) Colon cancer stem cells: implications in carcinogenesis. Front. Biosci. 16:1651-1662.
56. Gao W, et al. (2013) Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology. 145:636-646.e5.
57. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M. (2014) Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One. 9:e94621.
58. Kantara C, et al. (2015) Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/ metastasis. Lab. Invest. 95:100-112.
59. Harouaka R, Kang Z, Zheng S, Cao L. (2014) Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol. Ther. 141:209-221.
60. Alix-Panabieres C, Pantel K. (2014) Challenges in circulating tumour cell research. Nat. Rev. Cancer. 14:623-631.
61. Low WS, Wan Abas WA. (2015) Benchtop technologies for circulating tumor cells separation based on biophysical properties. Biomed Res. Int. 2015:239362.
62. Wang L, Asghar W, Demirci U, Wan Y. (2013) Nanostructured substrates for isolation of circulating tumor cells. Nano Today. 8:347-387.
63. Chen W, et al. (2013) Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano. 7:566-575.
64. Wan Y, et al. (2014) Nanostructured polystyrene well plates allow unbiased high-throughput characterization of circulating tumor cells. ACS Appl. Mater. Interfaces. 6:20828-20836.
65. Goda K, et al. (2012) High-throughput singlemicroparticle imaging flow analyzer. Proc. Natl. Acad. Sci. U. S. A. 109:11630-11635.
66. Reyes EE, et al. (2014) Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J. Transl. Med. 12:313.
67. Warkiani ME, et al. (2014) Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab Chip. 14:128-137.